Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts

c‐MYC controls more than 15% of genes responsible for proliferation, differentiation, and cellular metabolism in pancreatic as well as other cancers making this transcription factor a prime target for treating patients. The transcriptome of 55 patient‐derived xenografts show that 30% of them share a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bian, Benjamin, Bigonnet, Martin, Gayet, Odile, Loncle, Celine, Maignan, Aurélie, Gilabert, Marine, Moutardier, Vincent, Garcia, Stephane, Turrini, Olivier, Delpero, Jean‐Robert, Giovannini, Marc, Grandval, Philippe, Gasmi, Mohamed, Ouaissi, Mehdi, Secq, Veronique, Poizat, Flora, Nicolle, Rémy, Blum, Yuna, Marisa, Laetitia, Rubis, Marion, Raoul, Jean‐Luc, Bradner, James E, Qi, Jun, Lomberk, Gwen, Urrutia, Raul, Saul, Andres, Dusetti, Nelson, Iovanna, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376755/
https://www.ncbi.nlm.nih.gov/pubmed/28275007
http://dx.doi.org/10.15252/emmm.201606975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376755/
https://www.ncbi.nlm.nih.gov/pubmed/28275007
http://dx.doi.org/10.15252/emmm.201606975

Ejemplares similares